The prognosis of younger patients with prostate cancer is unclear, and the very few studies assessing those with metastatic castration-resistant prostate cancer (mCRPC) have mainly involved patients treated with older therapies. The aim of this observational study was to evaluate the clinical outcomes of a contemporary series of docetaxel-treated patients with mCRPC who were 60 years and younger.
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger
Zucali, Paolo Andrea;
2015-01-01
Abstract
The prognosis of younger patients with prostate cancer is unclear, and the very few studies assessing those with metastatic castration-resistant prostate cancer (mCRPC) have mainly involved patients treated with older therapies. The aim of this observational study was to evaluate the clinical outcomes of a contemporary series of docetaxel-treated patients with mCRPC who were 60 years and younger.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Uro Oncol-2015-Caffo.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
215.43 kB
Formato
Adobe PDF
|
215.43 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
